Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) saw a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 30,112 shares, an increase of 4,554.1% from the October 15th total of 647 shares. Based on an average daily trading volume, of 125,394 shares, the days-to-cover ratio is currently 0.2 days.
Ono Pharmaceutical Price Performance
Ono Pharmaceutical stock opened at $5.00 on Thursday. Ono Pharmaceutical has a 52-week low of $4.19 and a 52-week high of $5.75. The firm has a fifty day moving average of $5.01 and a 200-day moving average of $5.03.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and commercialization of prescription medicines. The company focuses on areas including oncology, immunology, neurology and other serious diseases, with an emphasis on discovering therapies that address unmet medical needs. Ono is best known for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb. Opdivo is used in multiple cancer indications, depending on regulatory approval in individual markets.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
